Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz

捐助

填料

Treatment of Ph-Like Acute Lymphoblastic Leukemia Ph-like ALL across the age spectrum has subsequently led to current precision medicine trials investigating the therapeutic potential of tyrosine kinase inhibitor-based therapies for children, adolescents, and adults with Ph-like ALL. These efforts have been somewhat challenging to translate given

Facet-Joints

Prophylaxis and Treatment of Central Nervous System (CNS) Acute Lymphoblastic Leukemiaotherapy. Despite great advancements, the CNS remains the most common site of extramedullary relapse, and treatment of CNS relapse remains clinically challenging in patients with ALL. This chapter will review current methods of diagnosing and treating CNS leukemia and evaluating risk of CNS relapse,

Thyroid-Gland

都相信我的話

The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)icities, the role of consolidation therapy following CAR T cell therapy, and the development of new cellular products to overcome observed mechanisms of resistance. Here we will review the relevant progress to date with the use of CAR T cells against B-ALL and discuss the limitations and future dire

legitimate

Clinical Management of Acute Lymphoblastic LeukemiaFrom Bench to Bedsid

genuine

Clinical Management of Acute Lymphoblastic Leukemia978-3-030-85147-7

我說不重要

剝削

Pierre-André Cornillon,Eric Matzner-L?berted agents for R/R disease is already having a positive impact. These approaches are currently being investigated in the frontline setting, bringing promise for continued outcome improvements, ideally with fewer adverse short- and long-term treatment effects.

MERIT

B. Bauer,A. Bouchard,P. Tripon,S. Rigalccess of highly effective therapies also to older and less fit patients. The possibility of devising largely chemotherapy-free regimens and avoiding allogeneic HSCT in an increasing proportion of patients is becoming a credible concept and marks a paradigm change for treatment of acute leukemias.